Stockscreener 앱 받기
18.57
1.59%
-0.30
시간 외 거래:
18.55
-0.02
-0.11%
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Oculis Holding AG (NASDAQ:OCS) Shares Bought by Geode Capital Management LLC - Defense World
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - The Manila Times
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in May 2025 - Nasdaq
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - GlobeNewswire Inc.
Oculis Updates Share Capital - The Manila Times
Long Term Trading Analysis for (OCSAW) - news.stocktradersdaily.com
(OCS) Trading Advice - news.stocktradersdaily.com
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
HC Wainwright Increases Oculis (NASDAQ:OCS) Price Target to $32.00 - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade - Defense World
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - The Manila Times
Stifel maintains Buy rating, $35 target on Oculis shares By Investing.com - Investing.com South Africa
Stifel maintains Buy rating, $35 target on Oculis shares - Investing.com
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day - TipRanks
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - The Manila Times
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis Completes Enrollment in Late-Stage Diabetic Macular Edema Trials - marketscreener.com
Oculis completes enrollment for pivotal DME treatment trials - Investing.com
Oculis Wraps Up Patient Enrollment in Late-stage Studies of Topical Eye Drug - MarketScreener
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - The Manila Times
REG-Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - TradingView
(OCS) Trading Signals - news.stocktradersdaily.com
A First Look At Oculis Holding AG: Revenues Still Several Years Away (NASDAQ:OCS) - Seeking Alpha
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond - The Manila Times
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - Defense World
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 14.1% in February - Defense World
Oculis' Insider Moves: A Glimpse into the Company's Future? - AInvest
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities - MarketScreener
Insider Buying: Oculis Holding Independent Director Bought CHF326k Of Shares - simplywall.st
Lionel Carnot Spends CHF326k On Oculis Holding Stock - Yahoo
Equities Analysts Set Expectations for Oculis Q1 Earnings - The AM Reporter
HC Wainwright Comments on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
Robert W. Baird Boosts Oculis (NASDAQ:OCS) Price Target to $41.00 - Defense World
HC Wainwright Lowers Oculis (NASDAQ:OCS) Price Target to $29.00 - Defense World
Oculis (NASDAQ:OCS) Sees Strong Trading Volume After Analyst Upgrade - Defense World
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update - Informazione.it
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Marketscreener.com
(OCS) Investment Analysis - Stock Traders Daily
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Stifel maintains Buy on Oculis shares, price target at $35 By Investing.com - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating By Investing.com - Investing.com South Africa
Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions - TipRanks
Oculis price target raised to $32 from $31 at BofA - TipRanks
Oculis (NASDAQ:OCS) Shares Gap Down Following Weak Earnings - Defense World
Oculis Holding AG Reports 2024 Financial Results - TipRanks
Oculis Reports 2024 Fourth Quarter Net Loss, Completes $100 Million Equity Financing to Support Pipeline - Vision Monday
0.39%
3.66%
자본화:
|
볼륨(24시간):